Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Universe Pharmaceuticals INC files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
33.2
30.7
48
40.1
32,309
23,024
17,859
Cost of revenue
19.8
16.6
22.7
18.3
21,994
16,953
11,558
Gross profit
13.4
14.1
25.3
21.9
10,315
6,072
6,301
Research and development
0.62
0.58
5.47
7.64
4,859
3,031
672
General and administrative
1.46
1.7
3.3
2.18
2,639
2,890
3,748
Operating expenses
3.65
3.84
11.7
28.9
14,281
14,092
9,217
Operating income
9.75
10.3
13.6
-7.02
-3,966
-8,020
-2,916
Interest expense
0.13
0.12
0.1
0.16
190
305
289
Other non-operating income
-0.1
-0.15
0.09
-0.07
-361
-101
-756
Pre-tax income
9.65
10.1
13.7
-7.09
-4,327
-8,121
-3,672
Income tax
2.1
2.54
2.36
0.82
2,254
607
Net income
7.55
7.56
11.3
-7.91
-6,581
-8,727
-3,672
EBITDA
10.2
10.7
14
-6.49
-3,457
-7,534
-2,398
EPS, basic
1,523.00
1,523.00
1,945.00
-1,309.00
-1,089.00
-626.96
-8.06
EPS, diluted
1,523.00
1,523.00
1,945.00
-1,309.00
-1,089.00
-626.96
-8.06
Shares, basic (weighted)
0
0
0.01
0.01
0.01
0.01
0.46
Shares, diluted (weighted)
0
0
0.01
0.01
0.01
0.01
0.46
Balance sheet
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
3.18
10.1
8.08
5,711
5,285
29,498
33,592
Short-term investments
13.7
13.1
13.2
Receivables
10.9
15.6
15.2
11
12,906
13,008
Inventory
1.91
2.46
2.21
3.34
1,737
2,193
Other current assets
1.72
0.04
852
39.9
Total current assets
23.3
50.5
41.5
25.3
51,638
53,604
Property, plant and equipment
4.43
4.68
4.25
3.7
3,568
3,584
Intangible assets
0.17
0.15
0.16
0.15
263
297
Total assets
28.8
70.1
59.5
41.7
67,953
69,303
Accounts payable
2.69
5.31
3.08
4.59
4,915
1,670
Deferred revenue
40.7
Short-term debt
2.65
4.33
3.94
5.48
5,857
2,107
Total current liabilities
8
11.2
13.1
13.8
20,313
13,174
Total liabilities
8
23.2
-35,271
13.8
22,450
13,174
Total debt
2,107
Paid-in capital
3.68
29.3
29.3
29.3
53,865
63,010
Retained earnings
13.7
25.1
16.3
-1.44
-10,172
-13,844
Other comprehensive income
0.9
2.09
-1.67
-2.37
-1,112
-1,814
Shareholders' equity
12.4
20.8
47
35,331
27,970
45,503
56,130
Total equity
12.4
20.8
47
35,331
27,970
45,503
56,130
Total liabilities and equity
28.8
70.1
59.5
41.7
67,953
69,303
Shares outstanding
0
0.04
3.63
0.01
0.04
0.56
Cash flow statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
7.55
7.56
11.3
-8.74
-6,581
-8,727
-3,672
Depreciation and amortization
0.42
0.41
0.45
0.53
509
486
517
Deferred income tax
-0.04
-0.01
-0.67
-0.54
1,568
607
Change in receivables
0.67
-4.11
-3.87
-1.53
4,718
-1,548
-169
Change in inventory
5.59
0.89
-0.45
0.02
-1,184
1,643
-475
Change in payables
-0.92
0.64
2.46
-1.92
1,641
144
-3,133
Cash from operations
13.2
6.12
-2.06
-1.3
1,117
-9,507
-5,052
Capital expenditures
-0.09
-0.05
-0.44
-0.09
-44.2
-208
-267
Acquisitions
-3.81
Purchases of investments
-15.3
Cash from investing
-0.09
-0.05
-27.1
-3.91
-44.2
-361
-342
Stock issued
25,000
15,000
Dividends paid
-16
Cash from financing
-16
0.47
26.6
3.32
-1,391
33,954
9,726
Exchange rate effect
-0.13
0.35
0.55
-0.47
-108
126
-238
Net change in cash
-3.01
6.88
-1.98
-2.37
-426
24,212
4,094
Free cash flow
13.1
6.06
-2.5
-1.4
1,073
-9,715
-5,319
Interest paid
0.14
0.16
0.15
0.2
190
305
289
Income taxes paid
2.26
2.17
3.27
2.75
864
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $4.75 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
35.3%
Gross profit / revenue.
Operating margin
-16.3%
Operating income / revenue.
EBITDA margin
-13.4%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-20.6%
Pre-tax income / revenue.
Net margin
-20.6%
Net income / revenue.
FCF margin
-29.8%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-28.3%
Cash from operations / revenue.
Return on equity (ROE)
-7.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-5.4%
Net income / average total assets.
Return on invested capital (ROIC)
-11.3%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
3.8%
Research and development expense / revenue.
Capex / revenue
1.5%
Capital expenditures / revenue.
D&A / revenue
2.9%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-22.4%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
663.4%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
257.2%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
3.8%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
560.3%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
238.9%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
23.4%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
16.7%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
385.5%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
2.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
951.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
374.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
3,175.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
322.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
147.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.07x
Current assets / current liabilities.
Quick ratio
3.54x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.55x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.04x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
3.0%
Total debt / total assets.
Liabilities / assets
19.0%
Total liabilities / total assets.
Net debt
-$31.48B
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$8.06
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$8.06
Net income per basic share, as reported (split-adjusted).
Revenue per share
$39,175.00
Revenue / diluted weighted shares.
FCF per share
-$11,668.00
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$11,083.00
Cash from operations / diluted weighted shares.
Book value per share
$99,637.00
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.00x
Market cap / revenue.
P/B
0.00x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.00x
Market cap / tangible book value, when positive.
FCF yield
-22,287.0%
Free cash flow / market cap.
Earnings yield
-15,386.0%
Net income / market cap (the inverse of P/E).
What was Universe Pharmaceuticals INC's revenue in fiscal 2025?
Universe Pharmaceuticals INC reported revenue of $17.86B for fiscal 2025, 22.4% lower than the year before.
Was Universe Pharmaceuticals INC profitable in fiscal 2025?
No. It reported a net loss of $3.67B.
How much free cash flow did Universe Pharmaceuticals INC generate in fiscal 2025?
Cash from operations of $5.05B minus capital expenditures of $266.8M left free cash flow of -$5.32B.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.